Stockscreener 앱 받기
4.62
3.59%
0.16
전일 마감가:
$4.46
열려 있는:
$4.655
하루 거래량:
10,569
Relative Volume:
0.11
시가총액:
$9.28M
수익:
-
순이익/손실:
$-17.10M
주가수익비율:
-0.0195
EPS:
-236.7281
순현금흐름:
$-15.92M
1주 성능:
-8.70%
1개월 성능:
-20.21%
6개월 성능:
-68.36%
1년 성능:
-44.54%
1일 변동 폭
$4.46
$4.655
1주일 범위
$4.10
$5.15
52주 변동 폭
$4.10
$41.80
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Company Profile
명칭
Quoin Pharmaceuticals Ltd Adr
전화
97299741444
주소
23 HATA'AS STREET, KFAR SABA
Compare QNRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QNRX
Quoin Pharmaceuticals Ltd Adr
|
4.62 | 9.34M | 0 | -17.10M | -15.92M | -236.73 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quoin Pharmaceuticals Ltd Adr 주식(QNRX)의 최신 뉴스
Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome - Sahm
Quoin Pharmaceuticals stock rises on rare disease IND filing By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals stock rises on rare disease IND filing - Investing.com
Number of shareholders of Quoin Pharmaceuticals. Ltd Sponsored ADR – FWB:2EB0 - TradingView
Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results - Sahm
Quoin Pharmaceuticals initiated with a Buy at Lucid Capital - TipRanks
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026 - Sahm
Quoin Pharmaceuticals DRC News Today (QNRX) - Investing.com
Quoin Pharmaceuticals provides regulatory update on QRX009 topical rapamycin - TipRanks
CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs - Sahm
Quoin Pharmaceuticals price target raised to $35 from $25 at Alliance Global - TipRanks
Quoin Pharmaceuticals (NASDAQ: QNRX) advances NS drug but warns on cash - Stock Titan
Quoin Pharmaceuticals provides update following QRX003 Type C meeting with FDA - TipRanks
Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026 - ChartMill
Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome - Sahm
Maxim Group Sticks to Its Buy Rating for Quoin Pharmaceuticals (QNRX) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CalciMedica (CALC) and Talphera (TLPH) - The Globe and Mail
Quoin Pharmaceuticals highlights continued growth of NETHERTON NOW program - TipRanks
Critical Contrast: Amneal Pharmaceuticals (NASDAQ:AMRX) versus Quoin Pharmaceuticals (NASDAQ:QNRX) - Defense World
This Quoin Pharmaceuticals Insider Increased Their Holding By 1,515,200% Last Year - Sahm
Quoin seeks orphan drug status in Japan for Netherton Syndrome therapy By Investing.com - Investing.com India
Quoin seeks orphan drug status in Japan for Netherton Syndrome therapy - Investing.com
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome - Sahm
Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome - ChartMill
ETFs Investing in Quoin Pharmaceuticals. Ltd Sponsored ADR Stocks - TradingView — Track All Markets
Quoin Pharmaceuticals Ltd – ADR trading resumes - MSN
Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Up 24.5% – Still a Buy? - Defense World
US Stock Market today: Nasdaq, S&P 500 open lower amid elevated tech valuation concerns, Dow Jones up 0.17% - Mint
Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results - Sahm
Quoin Pharmaceuticals director Langer buys $128,640 in ADSs - Investing.com
Why NioCorp Developments Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next? - ts2.tech
Quoin Pharmaceuticals stock soars after securing premium-priced funding - Investing.com
Why New Fortress Energy Shares Are Trading Higher By 41%; Here Are 20 Stocks Moving Premarket - Sahm
Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome - ChartMill
Quoin Pharmaceuticals finalizes separation agreement with former CFO - Investing.com
Quoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome - ChartMill
Quoin Pharmaceuticals advances rare disease pipeline with two active trials - Investing.com
Quoin Pharmaceuticals (QNRX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Quoin Pharmaceuticals receives FDA rare pediatric disease designation for QRX003 - Investing.com
QNRX Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Quoin Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com India
Quoin Pharmaceuticals regains Nasdaq compliance - Investing.com
Quoin Pharmaceuticals Ltd Share Price ADR EACH REPR 35 ORD SPON - Hargreaves Lansdown
QNRX Stock Plummets to 52-Week Low of $0.17 Amid Market Struggles - Investing.com
Quoin Pharmaceuticals CEO Michael Myers acquires $250,000 in shares - Investing.com
Quoin Pharmaceuticals granted extension to meet Nasdaq listing - Investing.com
Quoin Pharmaceuticals (QNRX) Stock Trends and Sentiment 2025 - MarketBeat
Quoin Pharmaceuticals (QNRX) Stock Forecast and Price Target 2026 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Tuesday's session: gap up and gap down stocks - ChartMill
Quoin Pharmaceuticals Ltd Adr (QNRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):